BLOG | Bluephage
Biotechnology and the growing popularity of rapid microbiological testing
According to the latest report on the global rapid and automated microbiological testing market 2022-2026, estimated at $5.9 billion in 2022, the market is projected to reach a revised size of $7.6 billion by 2026, growing at a CAGR of 6.1% during the analysis period.
Growth globally will be driven by increasing global prevalence of chronic infectious diseases, growing concerns about food safety, increased need for quick and easy diagnosis, rising public-private investments, research funding, grants, and continued technological advances.
Climate change and its drastic consequences in augmented heavy rains, floods, and droughts jeopardize water quality, especially at catchment points that could be fecally contaminated and need rapid detection before endangering public health.
Continuing technological advances to improve functionality, efficiency, effectiveness, rapid results, and accuracy are driving the adoption of microbial testing in academic institutes, research laboratories, hospitals, clinical laboratories, and biotech and pharmaceutical companies.
Rapid advances in microbial testing help overcome limitations such as prolonged exposure time to pathogenic strains and long procedure times associated with traditional testing methods. In addition, these tests serve as a cost-effective alternative to microbial identification by enabling a reduction in consumable cost per procedure.
- The trend toward laboratory automation bodes well for microbiological testing laboratories, which are turning to automation to increase throughput.
- The rising incidence of infectious diseases will drive demand for rapid microbiology testing, as infectious diseases remain the leading cause of death in underdeveloped regions, and rising healthcare spending in emerging markets will drive demand for automated microbiological testing.
- The focus on safe, high-quality food drives rapid microbiological testing, and automated rapid tests emerge as an attractive solution.
Bluephage is a biotechnology company that produces test kits to identify fecal and viral indicators in water. We use a recently patented technology to detect coliphages in the aquatic environment, as water without these coliphages is considered pathogen-free and, more importantly, safe drinking water.
Bluephage offers all-in-one solutions that streamline laboratory testing work and provides its customers with the necessary and disruptive elements for a new approach to water analysis that will revolutionize the way the world monitors water quality, making it the closest technique to real-time monitoring.